Male gender was recently reported as an adverse prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). We conducted a retrospective study of adult patients with DLBCL initially treated with rituximab containing regimens between 2001 and 2007. Patients were identified from the clinical archives of 43 Italian and Brazilian institutions. The principal endpoint was overall survival (OS). One thousand seven hundred and ninety-three patients were fully eligible for the study. Thirty-eight percent, 27%, 22% and 12% of patients had an International Prognostic Index (IPI) score of 0-1, 2, 3 and 4-5, respectively; 53% were males. After a median follow-up of 36 months (1-106), the 5-year OS was 76% (95% confidence interval 74-78%). In univariate analysis, male gender was an adverse prognostic factor with a hazard ratio of 1.52. In multivariate analysis, when adjusted by IPI, again gender maintained its prognostic relevance, showing an independent additive effect. In conclusion, in patients with DLBCL treated with rituximab containing regimens, gender may increase the predictive power of the IPI. Based on these results, given possible differences in blood clearance of rituximab between males and females, the benefit of higher doses of rituximab in males should be explored.

Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study / Carella, Angelo M; de Souza, Carmino A; Luminari, Stefano; Marcheselli, Luigi; Chiappella, Annalisa; di Rocco, Alice; Cesaretti, Marina; Rossi, Andrea; Rigacci, Luigi; Gaidano, Gianluca; Merli, Francesco; Spina, Michele; Stelitano, Caterina; Hohaus, Stefan; Barbui, Anna; Puccini, Benedetta; Miranda, Eliana C; Guida, Annalisa; Federico, Massimo. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 54:(2013), pp. 53-57. [10.3109/10428194.2012.691482]

Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study

LUMINARI, Stefano;MARCHESELLI, Luigi;CESARETTI, Marina;GUIDA, ANNALISA;FEDERICO, Massimo
2013

Abstract

Male gender was recently reported as an adverse prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). We conducted a retrospective study of adult patients with DLBCL initially treated with rituximab containing regimens between 2001 and 2007. Patients were identified from the clinical archives of 43 Italian and Brazilian institutions. The principal endpoint was overall survival (OS). One thousand seven hundred and ninety-three patients were fully eligible for the study. Thirty-eight percent, 27%, 22% and 12% of patients had an International Prognostic Index (IPI) score of 0-1, 2, 3 and 4-5, respectively; 53% were males. After a median follow-up of 36 months (1-106), the 5-year OS was 76% (95% confidence interval 74-78%). In univariate analysis, male gender was an adverse prognostic factor with a hazard ratio of 1.52. In multivariate analysis, when adjusted by IPI, again gender maintained its prognostic relevance, showing an independent additive effect. In conclusion, in patients with DLBCL treated with rituximab containing regimens, gender may increase the predictive power of the IPI. Based on these results, given possible differences in blood clearance of rituximab between males and females, the benefit of higher doses of rituximab in males should be explored.
54
53
57
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study / Carella, Angelo M; de Souza, Carmino A; Luminari, Stefano; Marcheselli, Luigi; Chiappella, Annalisa; di Rocco, Alice; Cesaretti, Marina; Rossi, Andrea; Rigacci, Luigi; Gaidano, Gianluca; Merli, Francesco; Spina, Michele; Stelitano, Caterina; Hohaus, Stefan; Barbui, Anna; Puccini, Benedetta; Miranda, Eliana C; Guida, Annalisa; Federico, Massimo. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 54:(2013), pp. 53-57. [10.3109/10428194.2012.691482]
Carella, Angelo M; de Souza, Carmino A; Luminari, Stefano; Marcheselli, Luigi; Chiappella, Annalisa; di Rocco, Alice; Cesaretti, Marina; Rossi, Andrea; Rigacci, Luigi; Gaidano, Gianluca; Merli, Francesco; Spina, Michele; Stelitano, Caterina; Hohaus, Stefan; Barbui, Anna; Puccini, Benedetta; Miranda, Eliana C; Guida, Annalisa; Federico, Massimo
File in questo prodotto:
File Dimensione Formato  
10428194%2E2012%2E691482.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 387.32 kB
Formato Adobe PDF
387.32 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1064418
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 37
social impact